Previous 10 | Next 10 |
home / stock / bct:cc / bct:cc news
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 12, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies for ca...
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 28, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies for c...
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 14, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies for c...
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 07, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies for c...
PHILADELPHIA and VANCOUVER, British Columbia, Aug. 04, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies for ca...
Extended survival and tumor shrinkage in advanced breast cancer patients who matched the immunotherapy HLA types, lead to the development of BriaCell’s prostate cancer program based on the patient’s HLA type. Bria-Pros™ is a novel off-the-shelf persona...
PHILADELPHIA and VANCOUVER, British Columbia, June 29, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies for ca...
Anti-Cancer activity of BriaCell’s lead candidate, Bria-IMT™, in advanced breast cancer patients was published in a leading peer-reviewed publication. Bria-IMT™, through a novel mechanism of action, rapidly destroyed tumors in patients who matched Bria...
PHILADELPHIA and VANCOUVER, British Columbia, May 18, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies for adv...
BriaCell CEO Dr. William V. Williams: FDA Fast Track Status for Cancer Treatment youtu.be BriaCell Therapeutics (NASDAQ:BCTX,NASDAQ:BCTXW,TSX:BCT) CEO Dr. William V. Williams discusses the US Food and Drug Administration (FDA) fast-track status the comp...
News, Short Squeeze, Breakout and More Instantly...
Briacell Therapeutics Corp. Company Name:
BCT:CC Stock Symbol:
TSXC Market:
Briacell Therapeutics Corp. Website:
A look at the top 10 most actives in Canada Canadian Natural Resources Limited (CNQ) rose 0.2% to $48.92 on volume of 19,781,731 shares iShares S&P/TSX 60 Index ETF (XIU) fell 0.5% to $34.3919 on volume of 13,629,336 shares Constellation Software Inc. Unsecured Subordinated Floating R...
A look at the top 10 most actives in Canada Constellation Software Inc. Unsecured Subordinated Floating Rate Debentures Series 1 (CSU.DB) rose 0.4% to $123 on volume of 12,106,000 shares Royal Bank of Canada (RY) rose 0.4% to $154 on volume of 4,630,267 shares iShares S&P/TSX 60 Index...
Progression free survival (PFS) extended to 9.1 months in ADC resistant patient - quadruple the PFS of patients in similar studies 1, 2, 3 Significant reduction of “Eye-Bulging” metastatic breast cancer tumor was previously rep...